1. Interplay of EMT and CSC in Cancer and the Potential Therapeutic Strategies
- Author
-
Horacio Cabral, Ryuichi Ono, Sabina Quader, and Shihori Tanabe
- Subjects
signaling pathway ,0301 basic medicine ,cancer stem cell ,Mini Review ,Population ,epithelial-mesenchymal transition ,Context (language use) ,Metastasis ,03 medical and health sciences ,0302 clinical medicine ,Cancer stem cell ,microRNA ,Medicine ,Pharmacology (medical) ,Epithelial–mesenchymal transition ,education ,Pharmacology ,education.field_of_study ,business.industry ,lcsh:RM1-950 ,Mesenchymal stem cell ,Cancer ,medicine.disease ,nanomedicine ,lcsh:Therapeutics. Pharmacology ,030104 developmental biology ,030220 oncology & carcinogenesis ,embryonic structures ,Cancer research ,business - Abstract
The mechanism of epithelial-mesenchymal transition (EMT) consists of the cellular phenotypic transition from epithelial to mesenchymal status. The cells exhibiting EMT exist in cancer stem cell (CSC) population, which is involved in drug resistance. CSCs demonstrating EMT feature remain after cancer treatment, which leads to drug resistance, recurrence, metastasis and malignancy of cancer. In this context, the recent advance of nanotechnology in the medical application has ascended the possibility to target CSCs using nanomedicines. In this review article, we focused on the mechanism of CSCs and EMT, especially into the signaling pathways in EMT, regulation of EMT and CSCs by microRNAs and nanomedicine-based approaches to target CSCs.
- Published
- 2020
- Full Text
- View/download PDF